Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

According to the company, the first trial of the Phase 3 study for the efficacy of itepekimab in adult former smokers with COPD met the primary target of showing a 27-percent reduction in the ...

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a ...

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

According to Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), the first trial of the Phase 3 study for the efficacy of itepekimab in adult former smokers with COPD met the primary target of showing ...

The second study didn't meet the primary endpoint despite a benefit seen earlier in the study, they added. Itepekimab was generally well tolerated in both studies, Sanofi and Regeneron said.

In a 1 a.m. Eastern time press release, Regeneron said one Phase 3 trial of itepekimab, in adult former smokers with COPD, met the primary target by showing significant reduction of 27% in the ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.